$6.37
0.215[3.49%]
At close: Apr 26
$6.37
0[0.00%]
After Hours: 4:20PM EDT
Relay Therapeutics
(NASDAQ:RLAY)Relay Therapeutics Stock (NASDAQ:RLAY), Analyst Ratings, Price Targets, Predictions
Relay Therapeutics Inc has a consensus price target of $29.68, established from looking at the 33 latest analyst ratings. The last 3 analyst ratings were released from Stifel, HC Wainwright & Co., and HC Wainwright & Co. on February 22, 2024, December 11, 2023, and November 8, 2023. With an average price target of $22 between Stifel, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 245.37% upside for Relay Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Stifel
HC Wainwright & Co.
Oppenheimer
JMP Securities
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Relay Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 02/22/2024 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 370.96% | Stifel | Bradley Canino | $25 → $30 | Maintains | Buy | Get Alert |
| 12/11/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 166.88% | HC Wainwright & Co. | Robert Burns | $19 → $17 | Maintains | Buy | Get Alert |
| 11/08/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 198.27% | HC Wainwright & Co. | Robert Burns | $33 → $19 | Maintains | Buy | Get Alert |
| 10/17/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 418.05% | HC Wainwright & Co. | Robert Burns | $30 → $33 | Maintains | Buy | Get Alert |
| 08/17/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 370.96% | HC Wainwright & Co. | Robert Burns | $32 → $30 | Maintains | Buy | Get Alert |
| 08/09/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 418.05% | Oppenheimer | Matthew Biegler | → $33 | Reiterates | Outperform → Outperform | Get Alert |
| 06/09/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 402.35% | HC Wainwright & Co. | Robert Burns | $46 → $32 | Maintains | Buy | Get Alert |
| 05/05/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 276.77% | JMP Securities | Silvan Tuerkcan | $28 → $24 | Maintains | Market Outperform | Get Alert |
| 04/20/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 96.23% | Jefferies | Akash Tewari | $16 → $12.5 | Upgrade | Underperform → Hold | Get Alert |
| 04/20/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 433.75% | Stifel | Bradley Canino | $38 → $34 | Maintains | Buy | Get Alert |
| 04/19/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 355.26% | JP Morgan | Eric Joseph | $42 → $29 | Maintains | Overweight | Get Alert |
| 04/19/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 339.56% | JMP Securities | Silvan Tuerkcan | → $28 | Reiterates | → Market Outperform | Get Alert |
| 04/19/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 355.26% | Raymond James | Dane Leone | → $29 | Upgrade | Outperform → Strong Buy | Get Alert |
| 04/19/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 135.48% | Barclays | Peter Lawson | $23 → $15 | Maintains | Equal-Weight | Get Alert |
| 04/18/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 418.05% | Oppenheimer | Matthew Biegler | → $33 | Maintains | Outperform | Get Alert |
| 04/13/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 355.26% | Raymond James | Dane Leone | → $29 | Initiates | → Outperform | Get Alert |
| 04/05/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 559.34% | JP Morgan | Eric Joseph | $45 → $42 | Maintains | Overweight | Get Alert |
| 03/07/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 622.14% | HC Wainwright & Co. | Robert Burns | $43 → $46 | Maintains | Buy | Get Alert |
| 02/03/2023 | RLAY | Buy Now | Relay Therapeutics | $6.37 | 418.05% | Oppenheimer | Matthew Biegler | → $33 | Initiates | → Outperform | Get Alert |
FAQ
What is the target price for Relay Therapeutics (RLAY)?
The latest price target for Relay Therapeutics (NASDAQ: RLAY) was reported by Stifel on February 22, 2024. The analyst firm set a price target for $30.00 expecting RLAY to rise to within 12 months (a possible 370.96% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Relay Therapeutics (RLAY)?
The latest analyst rating for Relay Therapeutics (NASDAQ: RLAY) was provided by Stifel, and Relay Therapeutics maintained their buy rating.
When was the last upgrade for Relay Therapeutics (RLAY)?
The last upgrade for Relay Therapeutics Inc happened on April 20, 2023 when Jefferies raised their price target to $12.5. Jefferies previously had an underperform for Relay Therapeutics Inc.
When was the last downgrade for Relay Therapeutics (RLAY)?
There is no last downgrade for Relay Therapeutics.
When is the next analyst rating going to be posted or updated for Relay Therapeutics (RLAY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relay Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relay Therapeutics was filed on February 22, 2024 so you should expect the next rating to be made available sometime around February 22, 2025.
Is the Analyst Rating Relay Therapeutics (RLAY) correct?
While ratings are subjective and will change, the latest Relay Therapeutics (RLAY) rating was a maintained with a price target of $25.00 to $30.00. The current price Relay Therapeutics (RLAY) is trading at is $6.37, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.